Who owns Endo Pharmaceuticals?
The company is 60 percent owned by investment firm Kelso & Company. The heritage of the Endo name dates to 1920 when five brothers of the Ushkow family established Endo Laboratories, a small pharmaceutical company, in Manhattan, New York.
Who bought Par Pharmaceuticals?
Endo International
Ireland-based Endo International has completed the $8.05bn acquisition of US-based Par Pharmaceutical Holdings from private investment firm TPG Capital North America.
Is Endo stock a buy?
Endo International plc – Sell Valuation metrics show that Endo International plc may be undervalued. Its Value Score of A indicates it would be a good pick for value investors. The financial health and growth prospects of ENDP, demonstrate its potential to outperform the market. It currently has a Growth Score of C.
Is Endo a public company?
Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system….Endo International.
| Type | public liability company |
|---|---|
| Website | endo.com |
Who is Endo Pharmaceuticals?
Endo Pharmaceuticals Inc. develops and markets high-value, quality branded pharmaceutical products for patients in need. Endo Pharmaceuticals’ specialty portfolio includes products for urology, men’s health, orthopedics and endocrinology. Learn More at EndoPharma.com
Why choose Endo International?
To meet the needs of today’s healthcare customers, Endo International’s businesses provide diverse products to help improve patients’ lives. High-value branded pharmaceutical products that meet the unmet needs of patients. Safe, innovative and cost-effective generic pharmaceutical products that help improve patient quality of life.
What three words summarize Endo Pharmaceuticals?
Better Outcomes. Insight. Effort. Results. These three words summarize Endo Pharmaceuticals. We listen to patients and doctors. We build on what we learn.
What are endendo’s specialty portfolios?
Endo Pharmaceuticals’ specialty portfolio includes products for urology, men’s health, orthopedics and endocrinology.